20/20 Biolabs (AIDX) risk factors, FY2025 10-K

Risks Related to Our Business and Industry

1. 01With limited exceptions, we have incurred losses since our inception, and we expect to continue to generate losses for the foreseeable future
2. 02Our success will depend heavily on our cancer screening and longevity tests
3. 03We will need to attract additional capital to scale our business but have no assurance that we can do so successfully
4. 04We will spend a substantial amount of our capital on test validation, biomarker and data acquisitions, data analytics and algorithm development, but our products might not succeed in gaining widespread market acceptance
5. 05The success of our diagnostic tests depends on the degree of market acceptance by physicians, patients, government agencies and others who influence medical decision making
6. 06We are expecting patient self-pay to constitute a significant portion of our revenues for the foreseeable future and this revenue growth is contingent upon individuals’ willingness to pay out of pocket for our diagnostic tests
7. 07The commercial potential of our longevity test is unknown and unproven
8. 08The interface between the DII and our laboratory information system has not yet been implemented
9. 09The viability of offering automated, tailored coupons for grocery purchases is untested and unproven by us
10. 10Our CLIAx and CLIAx fund might not contribute to our growth
11. 11We face substantial competition
12. 12Our inability to manage growth could harm our business
13. 13There are a limited number of manufacturers of molecular diagnostic equipment and related chemical reagents necessary for the provision of our diagnostic tests
14. 14Our suppliers may experience development or manufacturing problems or delays that could limit the growth of our revenue or increase our losses
15. 15To achieve widespread use of our diagnostic test and commercial scale, some individual consumers may need convenient access to blood draw services, but we cannot guarantee that these service providers will be willing to perform them
16. 16Our capillary blood collection devices are manufactured by other companies, and we cannot guarantee that we will have a continued supply of these devices or that the costs for them will not rise significantly
17. 17We have limited sales and marketing resources and few distribution resources for the commercialization of any diagnostic tests that we have developed
18. 18The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline
19. 19If we fail to enter into and maintain successful strategic alliances for diagnostic tests that we elect to co-develop, co-market, or out-license, we may have to reduce or delay our diagnostic test development or increase our expenditures
20. 20We may become dependent on possible future collaborations to develop and commercialize many of our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business
21. 21The success of our business is substantially dependent upon the efforts of our senior management team and our ability to attract additional personnel
22. 22Certain jurisdictions in which we may do business may not provide the same level of legal protections and enforcement of contract and intellectual property rights to which investors are accustomed in the United States
23. 23Adverse U.S. and global market, economic and political conditions, including the ongoing conflict between Ukraine and Russia, recent events in the Middle East and other events or circumstances beyond our control could have a material adverse effect on us
24. 24The obligations associated with being a public company will require significant resources and management attention, and we will incur increased costs
25. 25We may not complete our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective
26. 26We have previously restated our financial statements and may be required to restate our financial statements in the future, which could materially and adversely affect our business, financial condition, results of operations and the trading price of our securities

Risks Related to Intellectual Property

1. 27The preparation, filing, and prosecution of patent applications can be costly and time consuming
2. 28Our patents may not protect our diagnostic tests from competition
3. 29If we fail to meet our obligations under various license, license option, and technology transfer agreements, we may lose our rights to key technologies or data sources on which our business depends

Risks Related to Healthcare Government Regulation, Reimbursement, Product Safety and Effectiveness

1. 30We have relied on and expect to continue to rely on third parties to conduct studies of our diagnostics tests that will be required to meet our obligations under CLIA, CAP and/or other regulatory authorities and those third parties may not perform satisfactorily
2. 31We must successfully maintain and/or upgrade our information technology systems, and our failure to do so could have a material adverse effect on our business, financial condition or results of operations
3. 32Our business and operations could suffer in the event of system failures
4. 33International operations could subject us to risks and expenses that could adversely impact the business and results of operations
5. 34Our business is subject to various complex laws and regulations. We could be subject to significant fines and penalties if we or our partners fail to comply with these laws and regulations
6. 35New FDA regulations of lab tests could significantly impact our commercial operations
7. 36We are required to comply with federal and state laws governing the privacy of health information, and any failure to comply with these laws could result in material criminal and civil penalties
8. 37We are subject to federal and state healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws
9. 38If we become subject to claims relating to the receipt and handling of bio-hazardous materials (including infected blood), we could incur significant cost and liability
10. 39In the event that one or more lawsuits are filed against us, we could be subject to reputational risk

Risks Related to Ownership of Our Common Stock

1. 40We may not be able to maintain a listing of our common stock on Nasdaq
2. 41An active trading market may not develop or continue to be liquid, and the market price of our common stock may be volatile
3. 42We have never paid cash dividends on our common stock, and we do not intend to pay dividends for the foreseeable future
4. 43Future issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, could cause the market price of our common stock to decline and would result in the dilution of your holdings
5. 44Investors in our common stock may be unable to bring claims under Sections 11 and 12(a)(2) of the Securities Act due to the tracing requirement, which may limit the remedies available to investors in a direct listing
6. 45If securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our common stock could be negatively affected
7. 46If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares
8. 47We are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies and our stockholders could receive less information than they might expect to receive from more mature public companies
9. 48Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, and limit attempts by our stockholders to replace or remove our current management